KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) EBT (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed EBT for 16 consecutive years, with -$100.8 million as the latest value for Q4 2025.

  • Quarterly EBT fell 156.59% to -$100.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $466.9 million through Dec 2025, down 16.2% year-over-year, with the annual reading at $466.9 million for FY2025, 16.2% down from the prior year.
  • EBT for Q4 2025 was -$100.8 million at Halozyme Therapeutics, down from $219.0 million in the prior quarter.
  • The five-year high for EBT was $219.0 million in Q3 2025, with the low at -$100.8 million in Q4 2025.
  • Average EBT over 5 years is $93.5 million, with a median of $92.3 million recorded in 2021.
  • The sharpest move saw EBT skyrocketed 561.03% in 2021, then tumbled 156.59% in 2025.
  • Over 5 years, EBT stood at $54.8 million in 2021, then rose by 29.16% to $70.8 million in 2022, then surged by 42.92% to $101.2 million in 2023, then soared by 76.14% to $178.2 million in 2024, then crashed by 156.59% to -$100.8 million in 2025.
  • According to Business Quant data, EBT over the past three periods came in at -$100.8 million, $219.0 million, and $204.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.